𝔖 Bobbio Scriptorium
✦   LIBER   ✦

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

✍ Scribed by Cassidy, J; Clarke, S; Díaz-Rubio, E; Scheithauer, W; Figer, A; Wong, R; Koski, S; Rittweger, K; Gilberg, F; Saltz, L

Book ID
126649047
Publisher
Nature Publishing Group
Year
2011
Tongue
English
Weight
347 KB
Volume
105
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capecitabine plus oxaliplatin (XELOX) ve
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF